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Abstract
Background. Renal transplant recipients have a sig-
niﬁcantly reduced life expectancy, largely due to
premature cardiovascular disease. The aim of the cur-
rent analysis was to investigate the importance of time
of initiation of therapy after transplantation, on the
beneﬁts of statin therapy.
Methods. 2102 renal transplant recipients with total
cholesterol levels of 4.0–9.0mmol/l were randomly
assigned to treatment with ﬂuvastatin (n¼ 1050) or
placebo (n¼ 1052) and followed for a mean time of 5.1
years. The end-points were major cardiac events. The
average median time from transplantation to rando-
mization was 4.5 years (range: 0.5–29 years).
Results. In patients starting treatment with ﬂuvastatin
<4.5 years after renal transplantation, the incidence
of cardiac events was 4.6% over 5.1 years vs 9.2% in
those on placebo (P¼ 0.007). Fluvastatin signiﬁcantly
reduced the risk of cardiac death and non-fatal
myocardial infarction by 56% [risk ratio (RR): 0.44;
95% conﬁdence interval (95% CI): 0.26–0.74;
P¼ 0.002]. In a more detailed analysis patients were
grouped into 2-year intervals (since the last transplan-
tation). The frequency of cardiac death and non-fatal
myocardial infarction was reduced by 3.2%, 5.1%,
9.6% and 8.2% with ﬂuvastatin treatment as com-
pared to 6%, 10.4%, 13.4% and 9.6% with placebo
when treatment was initiated at 0–2, 2–4, 4–6 and >6
years, respectively. The risk reduction for patients
initiating therapy with ﬂuvastatin at years 0–2
(compared with >6 years) following transplantation
was 59% (RR: 0.41; 95% CI: 0.18–0.92; P¼ 0.0328).
This is also reﬂected in total time on renal replace-
ment therapy: in patients in the ﬁrst quartile
(<47 months) ﬂuvastatin use was associated with
a risk reduction of 64% compared with 19% for
patients in the fourth quartile (>120 months)
(P¼ 0.033).
Conclusions. Our data support an early introduction
of ﬂuvastatin therapy in a population of transplant
recipients at high risk of premature coronary heart
disease.
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Introduction
Renal transplant recipients have a signiﬁcantly reduced
life expectancy, largely due to premature cardiovas-
cular disease [1–3]. Many transplant recipients have
pre-existing cardiovascular disease at the time of
the transplantation, while immunosuppressive therapy
may aggravate existing risk factors or promote the
development of new ones, especially hyperlipidaemia
and hypertension [4]. Lipid-lowering treatment with
3-hydroxy-3-methylglutaryl coenzyme-A reductase
inhibitors (statins) has been shown to signiﬁcantly
reduce the incidence of cardiovascular events. Outcome
trials of statin therapy have demonstrated signiﬁcant
reductions in cardiovascular morbidity and mortality,
in both primary and secondary prevention popula-
tions [5–10], a beneﬁt that emerges 12 months after
initiation of treatment.
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In addition, in recent years, prospective and retro-
spective studies have indicated that statin therapy
should start immediately after an acute event [e.g.
myocardial infarction (MI)] in patients with established
coronary heart disease [11,12]. More recently, some
studies have suggested that the beneﬁt of statin therapy
is independent of the level of baseline cholesterol [9,10],
although this is not a universal ﬁnding [12].
In the ALERT Study [13], we found that treatment
with ﬂuvastatin reduced the incidence of major adverse
cardiovascular events (cardiac death, non-fatal MI
and coronary revascularizations) by 17% in renal
transplant recipients. Although the primary end-point
did not achieve statistical signiﬁcance, also due to lower
than anticipated rates of coronary revascularization in
the study population, this positive trend was supported
by a pre-speciﬁed, secondary end-point analysis that
included non-fatal MI and cardiac death. The risk of
cardiac death or deﬁnite non-fatal MI was reduced
signiﬁcantly, by 35% [13]. A further ﬁnding of the
ALERT Study, of major clinical importance, was to
demonstrate the safety and efﬁcacy of ﬂuvastatin when
administered together with immunosuppressive ther-
apy and a wide range of cardiovascular medication in
renal transplant recipients.
The current post-hoc analysis aimed to establish
the inﬂuence of the time since transplantation, prior
to initiation of statin therapy, on the beneﬁcial effects
of ﬂuvastatin therapy on cardiac death and non-
fatal MI.
Subjects and methods
The ALERT Study design and baseline data have been
described previously [14].
Brieﬂy, ALERT recruited 2102 renal transplant recipients
from nephrology units and transplant clinics in Northern and
Central Europe (Belgium, Denmark, Finland, Germany,
Norway, Sweden, Switzerland and the United Kingdom)
and Canada. Male and female patients, aged 30–75 years,
who had received a renal (or combined renal and pancreas)
transplant >6 months prior to randomization, with stable
graft function and with total serum cholesterol concentration
between 4.0 and 9.0mmol/l, were recruited. Patients with
a history of MI >6 months prior to randomization could
be enrolled if their total cholesterol levels ranged from 4.0
to 7.0mmol/l. Narrower total cholesterol ranges for inclusion
were used, if necessary, to satisfy the requirements of local
ethics committees. Patients were excluded if they were on
statin therapy or had a total cholesterol >9mmol/l
(>7mmol/l if previous MI), had familial hypercholesterolae-
mia or had experienced an acute rejection episode in the
3 months prior to randomization or a hospital-veriﬁed
infarction <6 months prior to randomization. Patients with
a predicted life expectancy of <1 year were also excluded.
In addition, patients with elevated liver function tests were
excluded.
The study adhered to the International Conference
on Harmonisation guidelines for Good Clinical Practice
and in accordance with the Declaration of Helsinki.
All participants provided written informed consent and the
ethics committee at each participating centre approved
the trial.
Trial procedure
Patients were initially randomized to receive either
ﬂuvastatin, 40mg/day (Lescol; Novartis Pharma AG, Basel,
Switzerland), or matching placebo. After 2 years, the dose
of the study drug was doubled for both groups after obtain-
ing written informed patient consent. The dose increase was
implemented on the recommendation of the independent
Data and Safety Monitoring Board [13] and based on
emerging safety data and clinical outcome trials published
after the design of ALERT that provided additional infor-
mation on the relationship between achieved low-density
lipoprotein (LDL)-cholesterol levels and reduction of car-
diovascular events. Patients were followed up for a minimum
of 5 and a maximum of 6 years. Study patients were seen
at 1.5 months following randomization and at 6-month
intervals thereafter [14].
End-point deﬁnition
The present report is a post-hoc analysis of the main
study, which was performed to evaluate the incidence of
major cardiac end-points (cardiac death or deﬁnite non-fatal
MI; primary end-point of the WOSCOP Study [5]) and the
effect of the interval between the last transplant and initiation
of ﬂuvastatin treatment. An adjudicated MI was classiﬁed
as deﬁnite if a new Q-wave developed in the presence of
abnormal cardiac markers or typical/atypical symptoms, or if
pathological ST-elevations and T-wave changes developed in
the presence of abnormal cardiac markers and typical/atypi-
cal symptoms. All deaths were considered cardiac unless an
unequivocal non-cardiac cause could be established.
Statistical analysis
In order to assess the potential impact of the interval between
transplantation and recruitment to the trial, we categorized
the population into subgroups determined by this time
interval. Analyses were performed in subgroups divided by
the median (4.5 years), in subgroups (0–2, 2–4, 4–6 and >6
years) of time since transplantation. The original sample size
calculation was performed assuming a 25% placebo Major
Cardiac Event rate after 5 years’ follow-up and a 25% effect
size. Using the chi-square test statistic for a difference bet-
ween two proportions, 1476 (738 per group) patients would
give a power of 83% to detect a difference between groups
using a two-sided test of size ¼ 0.05. Due to a lower than
expected incidence rate, the dose of ﬂuvastatin was doubled
and the sample size increased from 1700 to about 2100. Event
rates for the end-points described above are presented by
groupings. The Cox proportional hazards model was used to
generate risk ratios (RR) (ﬂuvastatin/placebo) for the event
rates and 95% conﬁdence intervals (95% CI) for those RR.
All analyses were carried out using SAS version 8 software.
Results
Between June 1996 and October 1997, 2102 patients
were randomly assigned to receive either ﬂuvastatin
Early statin use after renal transplantation 975
(n¼ 1050) or placebo (n¼ 1052). All eligible patients
were randomized and follow-up was sought for all
patients who were withdrawn early from the study.
The groups were well balanced with regard to baseline
demographic and clinical characteristics, as described
previously [2]. Angiotensin-converting enzyme (ACE)
inhibitors/angiotensin II blockers were used by 50%
and b-blockers by 60% of the patients; however, there
was no difference between the groups enrolled before
or after 4.5 years. More detailed baseline demograph-
ics, including traditional and transplant-related risk
factors, are shown in Table 1. Baseline cholesterol and
LDL-cholesterol were comparable between patients
enrolled in the trial<4.5 vs>4.5 years after transplanta-
tion. The effect of ﬂuvastatin on LDL- and total
cholesterol in both groups was comparable; absolute
reduction in LDL-cholesterol was 1.12 (0.0036) vs 1.11
(0.038) in patients transplanted <4.5 vs >4.5 years
prior to study entry. Figure 1 provides in detail the lipid
levels throughout the study, showing a similar effect
independent of the time-point of entry into the study.
The mean duration of follow-up was 5.1 years (SD 1.1);
the median follow-up was 5.4 years (interquartile
range: 5.2–5.6). The median time since last transplanta-
tion was 4.5 years (mean: 5.5 years).
In patients who initiated ﬂuvastatin treatment during
the ﬁrst 4.5 years after the transplant, the incidence of
cardiac death and non-fatal MI was 24 out of 522
(4.6%) in the ﬂuvastatin arm and 48 out of 521 (9.2%)
in the placebo arm. The risk of cardiac death and
non-fatal MI was reduced by 56% (RR: 0.44; 95% CI:
0.26–0.74; P¼ 0.002) as compared with the correspond-
ing placebo controls. There was a consistent pattern of
beneﬁt favouring ﬂuvastatin among the individual
components with a non-signiﬁcant 39% risk reduction
for cardiac death and a signiﬁcant 56% reduction in
the risk of non-fatal MI (Figure 2). The cumulative
rate (Kaplan–Meier event rates) for cardiac death and
non-fatal MI is shown in Figure 3.
To evaluate the impact of early ﬂuvastatin therapy
following transplantation on the risk of dying of
cardiac disease or suffering from non-fatal MI, the
study population was divided by 2-year intervals from
the last transplant.
In placebo controls, the risk of cardiac death and
non-fatal MI was higher in the ﬁrst 6 years following
transplantation (Figure 4). The frequency of cardiac
death and non-fatal MI was 3.2%, 5.1%, 9.6% and
8.2% with ﬂuvastatin treatment as compared to 6%,
10.4%, 13.4% and 9.6% with placebo when therapy
was initiated at 0–2, 2–4, 4–6 and>6 years after the last
transplant, respectively (Figure 4).
Renal function assessed by serum creatinine did
not differ throughout the study for patients on placebo
vs active treatment recruited either early or late into
the trial (Figure 5).
Table 1. Demographic data on the study population by time since last transplantation. Data are shown as means (SEM) or % total,
as described
<4.5 years after transplantation
(n¼ 1044)a
>4.5 years after transplantation
(n¼ 1058)a
Placebo (n¼ 521) Fluvastatin (n¼ 522) Placebo (n¼ 531) Fluvastatin (n¼ 527)
Demographic and clinical characteristics
Age (years) 49.8 (0.5) 49.0 (0.5) 50.2 (0.5) 49.9 (0.50)
Male [n (%)] 347 (66.6) 361 (69.2) 339 (63.8) 347 (64.3)
Diastolic BP (mmHg) 85.1 (0.4) 85.4 (0.4) 86.1 (0.4) 85.9 (0.50)
Systolic BP (mmHg) 143.8 (0.8) 143.8 (0.8) 144.3 (0.8) 143.8 (0.6)
BMI (kg/ma) 26.0 (0.2) 25.9 (0.2) 25.6 (0.2) 25.8 (0.2)
Total cholesterol (mmol/l) 6.4 (0.05) 6.5 (0.05) 6.5 (0.05) 6.4 (0.04)
LDL-cholesterol (mmol/l) 4.1 (0.05) 4.2 (0.05) 4.2 (0.04) 4.1 (0.05)
HDL-cholesterol (mmol/l) 1.3 (0.02) 1.3 (0.02) 1.3 (0.02) 1.3 (0.02)
Triglycerides (mmol/l) 2.3 (0.07) 2.3 (0.06) 2.2 (0.06) 2.2 (0.05)
First transplantation (%) 86.8 86.8 84.6 83.7
Total months on renal replacement therapy 57.1 (2.1) 56.6 (1.9) 119.7 (2.2) 120.2 (2.2)
Type of last transplant [n (%)]
Live donor 99 (19.0) 107 (20.5) 130 (24.5) 133 (25.2)
Cadaveric donor 422 (81.0) 415 (79.5) 400 (75.3) 794 (75.0)
Serum creatinine (mmol/l) 142 (2.2) 144 (2.4) 145 (2.4) 150 (2.5)
Traditional and transplant-related risk factors [n (%)]
History of angina pectoris or prior MI 47 (9.0) 45 (8.6) 54 (10.2) 55 (10.4)
Diabetes 102 (19.6) 111 (21.3) 97 (18.3) 86 (16.3)
Hypertension 385 (73.9) 410 (78.5) 392 (73.8) 388 (73.6)
Current smoker 96 (18.4) 103 (19.7) 89 (16.8) 101 (19.2)
HLA DR, two mismatches 75 (14.4) 78 (14.9) 84 (15.8) 91 (17.3)
Panel reactive antibodies 76 (14.6) 69 (13.2) 88 (16.6) 94 (17.8)
Treatment for rejections since last transplantation 208 (39.9) 214 (41.0) 240 (45.2) 240 (45.4)
Delayed graft function 94 (18.0) 82 (15.7) 91 (17.1) 98 (18.6)
aIntent-to-treat population.
BP, blood pressure; BMI, body mass index; MI, myocardial infarction.
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Discussion
The ALERT Study [13] is the largest interventional trial
in renal transplant recipients and conﬁrmed that the
beneﬁt associated with statin treatment observed in
the general population is also observed in renal trans-
plant recipients. However, despite compelling evidence
that statin therapy is beneﬁcial and reduces the risk
of cardiovascular complications, treatment with these
drugs has not yet become routine practice following
transplantation and in many cases the initiation of
statin treatment is delayed until clinical manifestation
of hypercholesterolaemia or the occurrence of the
ﬁrst cardiovascular event [15]. In this post-hoc analysis,
the importance of the early initiation of the statin
therapy became evident. In our analysis, the beneﬁt
of treatment with ﬂuvastatin was more evident the
earlier the treatment was initiated after transplantation.
Different use of potential cardioprotective drugs in
the groups could have a confounding effect on out-
come measures. However, the use of b-blockers, ACE
inhibitors or angiotensin-receptor blockers was not
different for any of the groups. Differences in renal
function might have had an inﬂuence on cardiac
end-points. However, no difference in serum creati-
nine was observed for patients entering the trial early
(<4.5 years) or late (>4.5 years) after transplantation.
The incidence of cardiac death and non-fatal MI
was reduced consistently in patients who started
ﬂuvastatin therapy in the ﬁrst 4.5 years following last
MI = Non-fatal Myocardial infarction; ITT = intention-to-treat population.
*By Cox proportional hazard model.
Risk Ratios for Cardiovascular end points in 
patients that initiated the treatment less than 4.5 y after the RT (ITT)
Cardiac death/MI 0.44 (0.26-0.74) 0.002
Cardiac death 0.61 (0.29-1.26) 0.183
MI 0.44 (0.23-0.84) 0.012
Risk ratio 
(95% CI) P value*
Favors fluvastatin Favors placebo
0.50 1.000.25 0.75 1.501.25
Risk ratio 
(95% CI) 
Fig. 2. Risk ratio for the composite end-point and the individual components.
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Fig. 1. LDL-cholesterol levels for patients in placebo and ﬂuvastatin arms, entering the trial before and after 4.5 years following renal
transplantation.
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transplantation. On the other hand, those patients who
started the therapy later had a smaller, statistically
insigniﬁcant beneﬁt. The risk of fatal and non-fatal
cardiac events was higher in the ﬁrst 6 years from last
transplant in the placebo control group and the risk
reduction seen with ﬂuvastatin was larger during this
same period. These observations are consistent with
the development of irreversible cardiovascular disease
with the passage of time following transplantation,
or the accumulation of multiple cardiovascular risk
factors with time that limit the beneﬁts of intervention
on a single risk factor.
We [16] and others have shown that lipid levels
rise immediately following transplantation, reaching
a maximum after 2–3 months, 20–30% higher than
pre-transplant levels. In one study, 6 months after
transplantation the level of total cholesterol exceeded
5.2mmol/l in 80% of patients and almost all patients
had an absolute coronary artery disease risk in excess
of 20% over 10 years [17]. The decision to initiate
treatment with statins is inﬂuenced by several factors.
In a recent retrospective study, Cosio et al. [18] reported
an increased trend in the use of statins in renal
transplant patients in the last decade. However, statin
therapy was initiated during the ﬁrst 2 years follow-
ing transplantation in only 32% of renal transplant
recipients; in 20% statins were initiated from the second
to the ﬁfth year after transplantation; and in the
remainder treatment was initiated later in the post-
transplant period. This might reﬂect the reluctance
of many physicians to prescribe statins to transplant
recipients due to concerns about potential interac-
tions between some statins and immunosuppres-
sive drugs and about the long-term use of these
combinations [19].
The main study report conﬁrmed the safety of
ﬂuvastatin in renal transplant recipients on chronic
immunosuppressive regimens with no increased risk of
malignancy, infection or musculoskeletal complications
[13]. The latter are of particular concern because many
of the commonly used statin drugs are metabolized by
the same microsomal enzymatic pathway (CYP3A4) as
calcineurin inhibitors, resulting in greatly increased
plasma levels of the statin and the potential for adverse
effects. Fluvastatin is not metabolized by CYP3A4
nor is it a substrate of p-glycoprotein-mediated trans-
porters [19] and is therefore ideal for use in transplant
recipients. This was highlighted by the absence of side
effects or adverse effects of ﬂuvastatin (compared with
placebo) in the ALERT Study.
Statin therapy is now considered a standard treat-
ment for patients who have had a cardiovascular event
and for those who are at equivalent coronary heart
disease risk. As a consequence, their use is mandated
in clinical guidelines. Renal transplant recipients should
be considered in this high-risk group due to the high
prevalence of cardiovascular risk factors and high
event rates. Although this is an exploratory, post-hoc
analysis and the data should not be overinterpreted,
P= 0.002
No of patients at Risk
Fluvastatin 522   512       502   487 468       417
Placebo   521 503 483   466   449      417
cumuKM lative rate for cardiac death and Non-fatal myocardial infarction in patients treated within 4.5
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Fig. 3. Kaplan–Meier analysis of survival time free of hard cardiac end-points (cardiac death and non-fatal MI) in patients treated within
the 4.5 years after transplantation.
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Fig. 4. Frequency of cardiac death or non-fatal MI divided by
every 2 year interval after transplantation.
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the ﬁndings support the increasing use of statins in
renal transplantation. The outcome data from ALERT
have been pivotal also in supporting the recent recom-
mendation for early and aggressive treatment of
dyslipidaemia in renal transplantation by K/DOQI
clinical practice guidelines for managing dyslipidaemias
in renal transplant recipients [20].
In conclusion, thedata in the current post-hocanalysis
support the introduction of ﬂuvastatin for treatment
of hyperlipidaemia in the early post-transplant period.
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